Comparative Pharmacology
Head-to-head clinical analysis: MANNITOL 15 IN PLASTIC CONTAINER versus OSMITROL 10 IN WATER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANNITOL 15 IN PLASTIC CONTAINER versus OSMITROL 10 IN WATER.
MANNITOL 15% IN PLASTIC CONTAINER vs OSMITROL 10% IN WATER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal blood flow, thereby enhancing water excretion.
Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 mL/hr, administer 50-100 g as 15-20% solution over 2-6 hours.
0.25-2 g/kg intravenously over 30-60 minutes, repeated every 6-12 hours as needed. Maximum dose: 2 g/kg per dose or 200 g daily.
None Documented
None Documented
Terminal elimination half-life approximately 0.5–1 hour in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Terminal elimination half-life is approximately 0.25–1.5 hours in patients with normal renal function, prolonged in renal impairment.
Renal: >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination (<2%).
Renal: >90% excreted unchanged by glomerular filtration with minimal tubular reabsorption. Negligible biliary/fecal elimination.
Category A/B
Category C
Osmotic Diuretic
Osmotic Diuretic